SCHEMBL4589867

SCHEMBL4589867

CC[C@H](C)[C@H](N)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CCCCN)C(=O)[O-].CC[C@H](C)[C@H](N)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CCCCN)C(=O)[O-].[Mn+2]

nearest known ligand 0.40

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PLG P00747 2/20 0.40
SLC15A2 Q16348 1/20 0.39
MMP1 P03956 1/20 0.39
GHSR Q92847 3/20 0.33
F2 P00734 2/20 0.33
CPB2 Q96IY4 1/20 0.33
NTSR2 O95665 1/20 0.32
NTSR1 P30989 1/20 0.32
OPRK1 P41145 2/20 0.32
OPRM1 P35372 1/20 0.32
ERAP2 Q6P179 1/20 0.32
ERAP1 Q9NZ08 1/20 0.32
LNPEP Q9UIQ6 1/20 0.32
CCNA2 P20248 2/20 0.32
CDK2 P24941 2/20 0.32
CCNA1 P78396 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5969687 0.98 PLG (0.40) PLGSLC15A2MMP1GHSRF2
SCHEMBL4588264 0.92 SLC15A2 (0.41) PLGSLC15A2MMP1GHSROPRK1
SCHEMBL4587382 0.92 SLC15A2 (0.41) PLGSLC15A2MMP1GHSROPRK1
SCHEMBL5969804 0.90 SLC15A2 (0.41) PLGSLC15A2MMP1GHSROPRK1
SCHEMBL2242457 0.90 SLC15A2 (0.41) PLGSLC15A2MMP1GHSROPRK1
SCHEMBL4588260 0.89 SLC15A2 (0.42) SLC15A2MMP1GHSRERAP2ERAP1
SCHEMBL2247601 0.88 SLC15A2 (0.42) SLC15A2MMP1GHSRERAP2ERAP1
SCHEMBL4587314 0.86 SLC15A2 (0.39) SLC15A2GHSRNTSR2NTSR1OPRK1
SCHEMBL31314430 0.86 FOLH1 (0.43) PLGSLC15A2F2CPB2NTSR2
SCHEMBL4588807 0.85 SLC15A2 (0.41) SLC15A2GHSROPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080255032-A1 METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING AGING OR PHOTODAMAGED SKIN PROCYTE CORPORATION (US) 2008-10-16 US disclosed
US-7384916-B2 Methods and compositions for preventing and treating aging or photodamaged skin PROCYTE CORPORATION (US) 2008-06-10 US disclosed
US-20060246029-A1 Methods and compositions for preventing and treating aging or photodamaged skin PROCYTE CORPORATION (US) 2006-11-02 US disclosed
US-20060018851-A1 Methods and compositions for preventing and treating hyperpigmentation of skin PROCYTE CORPORATION (US) 2006-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060246029-A1 Methods and compositions for preventing and treating aging or photodamaged skin RBP1, RBP4, SOD1 PLG 733/4885SLC15A2 2656/4885MMP1 625/4885
US-20060018851-A1 Methods and compositions for preventing and treating hyperpigmentation of skin RBP1, RBP4, MC1R PLG 1649/4885SLC15A2 1582/4885MMP1 1224/4885
US-20080255032-A1 METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING AGING OR PHOTODAMAGED SKIN RBP1, RBP4, SOD1 PLG 733/4885SLC15A2 2656/4885MMP1 625/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.